Lifileucel (Amtagvi) TIL Therapy for Cancer

Developing StoryLast updated JUN 12
SUMMARY

Australia's Therapeutic Goods Administration (TGA) granted conditional approval for Amtagvi (lifileucel) for advanced melanoma on June 4, 2026, marking the third global marketing authorization and the first T-cell therapy approved in Australia for a solid tumor cancer. As of June 12, 2026, multiple healthcare institutions are expanding access to TIL therapy, and real-world data shows Amtagvi achieved a 44% objective response rate (ORR) in advanced melanoma patients, an improvement over the 31% ORR from clinical trials. Iovance Biotherapeutics reported $60 million in U.S. Amtagvi revenue in Q1 2026, with a revised full-year forecast of $350-$370 million, while new TIL therapies like OBX-115 show promising efficacy with a 67% ORR in advanced nonuveal melanoma.

Timeline

Want updates on this thread?

Track this story

June 2026 — 6 developments

  1. Real-world safety outcomes with lifileucel in advanced melanoma patients were discussed at ASCO 2026…

    Real-world safety outcomes with lifileucel in advanced melanoma patients were discussed at ASCO 2026, revealing prolonged cytopenias and post-treatment infections in some cases, though organ dysfunction and immune-related toxicities were low. Researchers suggested adjusting the lymphodepleting chemotherapy regimen might improve the safety profile of lifileucel treatment. Significant logistical challenges, including referral processes and manufacturing timelines up to 60 days, are crucial for the successful implementation of TIL therapies.

  2. Multiple healthcare institutions, including Corewell Health, NYU Langone, and Fox Chase Cancer Cente…

    Multiple healthcare institutions, including Corewell Health, NYU Langone, and Fox Chase Cancer Center, are now offering or expanding access to TIL therapy for advanced melanoma patients. This development broadens the availability of this cutting-edge treatment beyond regulatory approvals and clinical trial presentations.

  3. The phase 1/2 Agni-01 trial presented at the 2026 ASCO Annual Meeting showed encouraging efficacy fo…

    The phase 1/2 Agni-01 trial presented at the 2026 ASCO Annual Meeting showed encouraging efficacy for OBX-115 engineered TIL cell therapy in patients with advanced nonuveal melanoma. Among 15 patients treated at the recommended phase 2 dose, the objective response rate (ORR) was 67%, with a manageable safety profile that appears to differentiate from the current standard TIL therapy, lifileucel.

  4. Advances in TIL therapy were highlighted at the 2026 ASCO Meeting, including IL-15-enhanced approach…

    Advances in TIL therapy were highlighted at the 2026 ASCO Meeting, including IL-15-enhanced approaches aimed at reducing toxicity and expanding applications to traditionally resistant tumors. A novel therapy from Obsidian demonstrated a 63% response rate and a 93% disease control rate. These developments suggest broader progress in TIL therapy beyond Amtagvi.

  5. Real-world data presented at the 2026 Tandem Meetings showed Amtagvi achieved a 44% objective respon…

    Real-world data presented at the 2026 Tandem Meetings showed Amtagvi achieved a 44% objective response rate (ORR) in advanced melanoma patients, an improvement over the 31% ORR from clinical trials. Iovance Biotherapeutics is also investigating Amtagvi in frontline advanced melanoma and other solid tumor types, and has received Investigational New Drug (IND) clearance for a new IL-12 tethered TIL therapy.

  6. Australia's Therapeutic Goods Administration (TGA) has granted conditional approval for Amtagvi (lifileucel) for the treatment of advanced melanoma.

    Australia's Therapeutic Goods Administration (TGA) has granted conditional approval for Amtagvi (lifileucel) for the treatment of advanced melanoma. This marks the third global marketing authorization for the therapy and the first T-cell therapy approved in Australia for a solid tumor cancer.

May 2026 — 2 developments

  1. Iovance Biotherapeutics reported strong first-quarter 2026 financial results, with total revenue of approximately $71 million, a 45% year-over-year increase.

    Iovance Biotherapeutics reported strong first-quarter 2026 financial results, with total revenue of approximately $71 million, a 45% year-over-year increase. Amtagvi (lifileucel) contributed around $60 million in U.S. revenue, leading Iovance to revise its full-year 2026 revenue forecast upwards to $350-$370 million.

  2. Recent analyses of the Phase 2 C-144-01 trial for Amtagvi (lifileucel) revealed a 20% five-year surv…

    Recent analyses of the Phase 2 C-144-01 trial for Amtagvi (lifileucel) revealed a 20% five-year survival rate in advanced melanoma patients previously treated with checkpoint inhibitors. The therapy demonstrated a 31.4% objective response rate with a median duration of response of 36.5 months, and nearly a third of responders maintained their response at the five-year mark.

April 2026 — 1 developments

  1. Obsidian Therapeutics and Galera Therapeutics announced a merger in mid-April 2026 to advance OBX-115, a next-generation TIL therapy.

    Obsidian Therapeutics and Galera Therapeutics announced a merger in mid-April 2026 to advance OBX-115, a next-generation TIL therapy. This merger aims to improve upon existing treatments by potentially eliminating the need for high-dose interleukin-2 and enabling outpatient administration.

March 2026 — 2 developments

  1. The FDA issued a letter in March 2026 regarding promotional materials for Amtagvi (lifileucel), expr…

    The FDA issued a letter in March 2026 regarding promotional materials for Amtagvi (lifileucel), expressing concerns about potentially misleading efficacy claims, particularly concerning overall survival data from single-arm studies.

  2. Real-world data presented at the 2026 Tandem Meetings indicated an overall response rate of 44% for …

    Real-world data presented at the 2026 Tandem Meetings indicated an overall response rate of 44% for lifileucel TIL therapy, with higher responses observed in patients treated earlier in their disease course. The 8th TIL Therapies Summit in 2026 focuses on advancing TIL therapy for solid tumors beyond melanoma.

February 2026 — 7 developments

  1. Iovance Biotherapeutics has received FDA Fast Track designation for its lifileucel (TIL) therapy in non-small cell lung cancer.

    Iovance Biotherapeutics has received FDA Fast Track designation for its lifileucel (TIL) therapy in non-small cell lung cancer. This designation expands the potential applications of lifileucel beyond its current focus on sarcomas and melanoma. The company is also planning a registrational trial for lifileucel in soft tissue sarcomas.

  2. Iovance Biotherapeutics announced positive early pilot data for lifileucel (Amtagvi) in soft tissue …

    Iovance Biotherapeutics announced positive early pilot data for lifileucel (Amtagvi) in soft tissue sarcomas, showing a 50% confirmed objective response rate in early evaluable patients. Ochsner MD Anderson Cancer Center has also begun offering TIL therapy for advanced melanoma. Iovance reported approximately $220 million in Amtagvi sales in the U.S. for 2025.

  3. Iovance Biotherapeutics announced positive early data from a pilot clinical trial of lifileucel (TIL…

    Iovance Biotherapeutics announced positive early data from a pilot clinical trial of lifileucel (TIL cell therapy) in patients with advanced undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS). The trial, supported by Iovance and led by Memorial Sloan Kettering Cancer Center, showed compelling response rates in patients refractory to frontline treatments. Iovance plans to initiate a registrational trial in the second quarter of 2026.

  4. Iovance Biotherapeutics announced positive results from its first clinical trial of lifileucel (Amtagvi) TIL cell therapy in patients with advanced soft tissue sarcomas.

    Iovance Biotherapeutics announced positive results from its first clinical trial of lifileucel (Amtagvi) TIL cell therapy in patients with advanced soft tissue sarcomas. The trial showed compelling response rates, demonstrating potential to address a significant unmet need in patients refractory to frontline treatments. Iovance plans to initiate a registrational trial in the second quarter.

  5. Vanderbilt-Ingram Cancer Center has treated its first patient in a newly launched tumor-infiltrating lymphocyte (TIL) therapy program.

    Vanderbilt-Ingram Cancer Center has treated its first patient in a newly launched tumor-infiltrating lymphocyte (TIL) therapy program. This personalized treatment involves isolating, expanding, and re-infusing a patient's own white blood cells to fight tumors. The therapy is currently approved and marks a new institutional application of TIL therapy for melanoma.

  6. Retrospective analysis of lifileucel (Amtagvi) therapy in advanced melanoma patients shows an objective response rate (ORR) of 44% and a disease control rate (DCR) of 73%.

    Retrospective analysis of lifileucel (Amtagvi) therapy in advanced melanoma patients shows an objective response rate (ORR) of 44% and a disease control rate (DCR) of 73%. These real-world data exceed the ORR of 31% from the clinical trial that supported its accelerated FDA approval. A separate study also indicates that while a portion of referred patients proceed to TIL therapy, those who receive it show improved overall survival.

December 2025 — 1 developments

October 2025 — 1 developments

  1. Further discussion on next-generation engineered TILs, including CRISPR gene editing and IL-2 toxicity elimination, highlights ongoing innovation in the field.

    Further discussion on next-generation engineered TILs, including CRISPR gene editing and IL-2 toxicity elimination, highlights ongoing innovation in the field.

September 2025 — 1 developments

  1. The 2025 ASCO Annual Meeting showcases significant advancements in TIL therapy, including novel monotherapies (e.

    The 2025 ASCO Annual Meeting showcases significant advancements in TIL therapy, including novel monotherapies (e.g., LM103, OBX-115, GT101, GT300, GT201, HS-IT101) and combination regimens for various solid tumors.

July 2025 — 1 developments

  1. The American Cancer Society provides an overview of TIL therapy, explaining how it uses a patient's …

    The American Cancer Society provides an overview of TIL therapy, explaining how it uses a patient's own immune cells to fight cancer and its potential benefits, including long-lasting responses.

June 2025 — 1 developments

  1. Five-year follow-up trial results for Lifileucel are published, providing further long-term efficacy data for the approved therapy.

    Five-year follow-up trial results for Lifileucel are published, providing further long-term efficacy data for the approved therapy.

May 2025 — 1 developments

  1. MedStar Georgetown University Hospital is now offering breakthrough Tumor-Infiltrating Lymphocyte (T…

    MedStar Georgetown University Hospital is now offering breakthrough Tumor-Infiltrating Lymphocyte (TIL) therapy for metastatic melanoma patients who have not responded to previous treatments. This marks a new phase in the therapy's availability to patients.

December 2024 — 1 developments

  1. Lifileucel is formally incorporated into the 2024 NCCN Guidelines as a preferred second-line regimen for advanced melanoma, solidifying its place in standard oncology practice.

    Lifileucel is formally incorporated into the 2024 NCCN Guidelines as a preferred second-line regimen for advanced melanoma, solidifying its place in standard oncology practice.

November 2024 — 1 developments

  1. Dr. Allison Betof Warner discusses TIL therapy for advanced melanoma, highlighting its potential to …

    Dr. Allison Betof Warner discusses TIL therapy for advanced melanoma, highlighting its potential to overcome resistance to other therapies and its role in the future of melanoma care.

October 2024 — 1 developments

  1. An industry insight report discusses the FDA approval of Lifileucel, the expanding pipeline of over …

    An industry insight report discusses the FDA approval of Lifileucel, the expanding pipeline of over 75 TIL-based therapies, and more than 100 clinical trials globally, projecting significant market growth.

May 2024 — 2 developments

  1. An article details the 30+ year journey of TIL therapy, from its discovery to the recent FDA approva…

    An article details the 30+ year journey of TIL therapy, from its discovery to the recent FDA approval of Lifileucel, and discusses ongoing research to enhance its efficacy and expand applications.

  2. Stanford Cancer Institute highlights the promise of TIL therapy, noting its potential for a wide arr…

    Stanford Cancer Institute highlights the promise of TIL therapy, noting its potential for a wide array of solid tumors beyond melanoma and the significant advancements in the past 5-10 years that made it a viable treatment option.

April 2024 — 1 developments

  1. Stanford Cancer Institute performs the world's first commercially approved infusion of Lifileucel for advanced melanoma, marking its entry into routine clinical practice.

    Stanford Cancer Institute performs the world's first commercially approved infusion of Lifileucel for advanced melanoma, marking its entry into routine clinical practice.

March 2024 — 1 developments

  1. The National Cancer Institute publishes a blog post detailing the historic FDA approval of Lifileucel (Amtagvi), emphasizing its significance after decades of research.

    The National Cancer Institute publishes a blog post detailing the historic FDA approval of Lifileucel (Amtagvi), emphasizing its significance after decades of research.

February 2024 — 3 developments

  1. Scientists have captured, for the first time, immune cells (macrophages) actively attacking and engu…

    Scientists have captured, for the first time, immune cells (macrophages) actively attacking and engulfing live melanoma cells, a discovery that could open new avenues for melanoma treatment. Real-world data presented in early 2026 also indicates lifileucel (Amtagvi) achieved an objective response rate (ORR) of 44% in advanced melanoma patients, with earlier intervention showing higher response rates.

  2. A recent study suggests lifileucel (Amtagvi) TIL therapy can be safely and effectively administered …

    A recent study suggests lifileucel (Amtagvi) TIL therapy can be safely and effectively administered to high-risk metastatic melanoma patients using a reduced-dose lymphodepleting conditioning regimen. This modification may broaden eligibility for the treatment, which was previously inaccessible to some patients with poor performance status.

  3. The FDA grants accelerated approval to Lifileucel (Amtagvi) for the treatment of unresectable or met…

    The FDA grants accelerated approval to Lifileucel (Amtagvi) for the treatment of unresectable or metastatic melanoma in patients previously treated with other therapies, marking the first FDA-approved TIL therapy and the first cell-based immunotherapy for a solid tumor.

December 2023 — 1 developments

  1. Researchers report that nearly 50% of patients treated with investigational Lifileucel were alive fo…

    Researchers report that nearly 50% of patients treated with investigational Lifileucel were alive four years post-treatment, with the median duration of response not yet reached, indicating potential for long-term benefits.

January 2023 — 1 developments

  1. A report highlights that TIL therapy shows significantly longer progression-free survival in stage I…

    A report highlights that TIL therapy shows significantly longer progression-free survival in stage IIIC and IV melanoma patients compared to current recommended therapies, with some studies reporting a 50% overall response rate.

January 2022 — 1 developments

  1. Studies show TIL therapy to be effective against metastatic melanomas that are refractory to prior treatments, yielding superior outcomes compared to ipilimumab.

    Studies show TIL therapy to be effective against metastatic melanomas that are refractory to prior treatments, yielding superior outcomes compared to ipilimumab.

January 2021 — 1 developments

  1. Iovance Biotherapeutics successfully conducts Phase II trials (LN-144) for Lifileucel in advanced me…

    Iovance Biotherapeutics successfully conducts Phase II trials (LN-144) for Lifileucel in advanced melanoma patients who have progressed after immune checkpoint inhibitor treatment, demonstrating an 80% disease control rate.

January 2020 — 1 developments

  1. Rosenberg and colleagues identify a specific subset of TILs, known as stem-like lymphocytes, as being responsible for antitumor activity, enhancing understanding of TIL efficacy.

    Rosenberg and colleagues identify a specific subset of TILs, known as stem-like lymphocytes, as being responsible for antitumor activity, enhancing understanding of TIL efficacy.

January 2017 — 1 developments

  1. TIL therapy is reported to be successful in treating uveal melanoma, a rare and refractory form of the disease.

    TIL therapy is reported to be successful in treating uveal melanoma, a rare and refractory form of the disease.

January 2011 — 1 developments

  1. The National Cancer Institute enters a cooperative research agreement with Iovance Biotherapeutics t…

    The National Cancer Institute enters a cooperative research agreement with Iovance Biotherapeutics to advance the development of TIL therapy, including larger clinical trials and manufacturing infrastructure.

January 2009 — 1 developments

  1. Moffitt Cancer Center becomes the first institution outside the NCI to offer TIL therapy to melanoma patients, adopting the NCI protocol.

    Moffitt Cancer Center becomes the first institution outside the NCI to offer TIL therapy to melanoma patients, adopting the NCI protocol.

January 2000 — 2 developments

  1. A simplified method for culturing TILs is developed, helping to keep the cells active for longer and improving the therapy's practicality.

    A simplified method for culturing TILs is developed, helping to keep the cells active for longer and improving the therapy's practicality.

  2. Researchers discover that lymphodepleting chemotherapy prior to TIL infusion significantly increases…

    Researchers discover that lymphodepleting chemotherapy prior to TIL infusion significantly increases response rates, leading to a 56% response rate in heavily treated metastatic melanoma patients.

January 1994 — 1 developments

  1. Final results from an expanded clinical trial involving 86 metastatic melanoma patients treated with TILs are published, showing a 34% response rate.

    Final results from an expanded clinical trial involving 86 metastatic melanoma patients treated with TILs are published, showing a 34% response rate.

January 1988 — 1 developments

  1. The first experimental use of TIL therapy in humans begins, with Rosenberg and colleagues treating 2…

    The first experimental use of TIL therapy in humans begins, with Rosenberg and colleagues treating 20 patients with metastatic melanoma, showing promising preliminary results of tumor regressions.

January 1986 — 1 developments

  1. Dr. Steven Rosenberg and colleagues at the National Cancer Institute (NCI) discover tumor-infiltrati…

    Dr. Steven Rosenberg and colleagues at the National Cancer Institute (NCI) discover tumor-infiltrating lymphocytes (TILs) in human tumors and develop a protocol to expand them in the lab, demonstrating their ability to cause tumor regression in mice.